Michael Hughes

TL;DR: In this article, the efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear.

TL;DR: In this article, a double-blind study evaluated treatment with either a single nucleoside or two nucleosides in adults infected with human immunodeficiency virus type 1 (HIV-1) whose CD4 cell counts were from 200 to 500 per cubic millimeter.

TL;DR: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF at high risk of stroke (CHADS(2) score of ≥ 2) and at lower levels of stroke risk, antithROMbotic treatment decisions will require a more individualized approach.

TL;DR: Evidence is presented that Drosophila immune-competent cells have the potential to express more than 18,000 isoforms of the immunoglobulin-superfamily receptor Down syndrome cell adhesion molecule (Dscam), and the molecular diversity of Dscam transcripts generated through a mechanism of alternative splicing is highly conserved across major insect orders, suggesting an unsuspected molecular complexity of the innate immune system of insects.

TL;DR: Overall, the reporting of clinical trials appears to be biased toward an exaggeration of treatment differences, and more emphasis should be given to the magnitude of treatment Differences and to estimation methods such as confidence intervals.